THE IMPORTANCE OF ANTIMULLERIAN HORMONE IN DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME

Not Applicable

• Conditions: Health Condition 1: null- Patients attending theendocrine clinic for menstrualirregularities, hyperandrogenism orinfertility

• Registration Number: CTRI/2017/02/007800
• Lead Sponsor: Sanjay Gandhi Postgraduate Institute of medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 280

Inclusion Criteria

Patients attending the endocrine clinic for menstrual irregularities, hyperandrogenism or infertility were recruited

Exclusion Criteria

Age < 18 years

Patients with other causes like hypergonadotrophic hypogonadism, hypogonadism due to pituitary lesion, 21-hydroxylase-deficient nonclassic adrenal hyperplasia, Thyroid dysfunction, Hyperprolactinemia, Neoplastic androgen secretion, Drug induced androgen excess, Cushingâ??s syndrome

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To calculate diagnostic power of serum AMH levels in diagnosis of PCOS <br/ ><br>2) To assess relationship between Polycystic Ovarian Morphology and AMH levels.Timepoint: Final outcome will be assessed at April 2017

Secondary Outcome Measures

Name	Time	Method
To assess whether AMH level can replace ultrasound in diagnosis of PCOSTimepoint: Will be assessed at April 2017